Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Connect Biopharma Holdings ( (CNTB) ) has shared an update.
On May 13, 2025, Connect Biopharma announced the initiation of its Phase 2 Seabreeze STAT Asthma study after receiving agreement on the final study protocol from the FDA. This study aims to evaluate the safety and efficacy of rademikibart as an adjunct treatment for acute exacerbations in asthma patients. The study’s initiation follows positive results from a prior Phase 2 trial, highlighting rademikibart’s potential to rapidly improve lung function. The company plans to report topline data in the first half of 2026, positioning rademikibart as a potentially significant treatment for acute asthma exacerbations.
The most recent analyst rating on (CNTB) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Connect Biopharma Holdings stock, see the CNTB Stock Forecast page.
Spark’s Take on CNTB Stock
According to Spark, TipRanks’ AI Analyst, CNTB is a Neutral.
Connect Biopharma Holdings’ overall score reflects the challenges of unprofitability and negative cash flow despite recent revenue growth and a strong balance sheet. Technical indicators suggest a bearish trend, while the valuation highlights the risks typical of early-stage biotech firms. However, the positive corporate event regarding FDA support for Phase 2 trials offers a promising growth opportunity in the pipeline, improving the outlook.
To see Spark’s full report on CNTB stock, click here.
More about Connect Biopharma Holdings
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company based in San Diego, California, focused on transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, targeting acute exacerbations in asthma and COPD patients.
Average Trading Volume: 114,396
Technical Sentiment Signal: Sell
Current Market Cap: $44.41M
See more data about CNTB stock on TipRanks’ Stock Analysis page.